Publications

Vicario R, Fragkogianni S, Weber L, Lazarov T, Hu Y, Hayashi SY, Craddock BP, Socci ND, Alberdi A, Baako A et al..  2024.  A microglia clonal inflammatory disorder in Alzheimer's Disease.. bioRxiv.

Gilvary C, Madhukar N, Elkhader J, Elemento O.  2019.  The Missing Pieces of Artificial Intelligence in Medicine.. Trends Pharmacol Sci. 40(8):555-564.

Ertl IE, Lemberger U, Ilijazi D, Hassler MR, Bruchbacher A, Brettner R, Kronabitter H, Gutmann M, Vician P, Zeitler G et al..  2022.  Molecular and Pharmacological Bladder Cancer Therapy Screening: Discovery of Clofarabine as a Highly Active Compound.. Eur Urol. 82(3):261-270.

Tan AY, Michaeel A, Liu G, Elemento O, Blumenfeld J, Donahue S, Parker T, Levine D, Rennert H.  2014.  Molecular diagnosis of autosomal dominant polycystic kidney disease using next-generation sequencing.. J Mol Diagn. 16(2):216-28.

Matrai CE, Ohara K, Eng KWha, Glynn SM, Chandra P, Chatterjee-Paer S, Motanagh S, Mirabelli S, Kurtis B, He B et al..  2022.  Molecular Evaluation of Low-grade Low-stage Endometrial Cancer With and Without Recurrence.. Int J Gynecol Pathol. 41(3):207-219.

Maura F, Ziccheddu B, Xiang JZ, Bhinder B, Rosiene J, Abascal F, Maclachlan KH, Eng KWha, Uppal M, He F et al..  2023.  Molecular Evolution of Classic Hodgkin Lymphoma Revealed Through Whole-Genome Sequencing of Hodgkin and Reed Sternberg Cells.. Blood Cancer Discov. 4(3):208-227.

Matrai C, Motanagh S, Mirabelli S, Ma L, He B, Chapman-Davis E, Kurtis B, Elemento O, Mosquera JMiguel, Ellenson LH.  2020.  Molecular Profiles of Mixed Endometrial Carcinoma.. Am J Surg Pathol. 44(8):1104-1111.

Nolan DJ, Ginsberg M, Israely E, Palikuqi B, Poulos MG, James D, Ding B-S, Schachterle W, Liu Y, Rosenwaks Z et al..  2013.  Molecular signatures of tissue-specific microvascular endothelial cell heterogeneity in organ maintenance and regeneration.. Dev Cell. 26(2):204-19.

Ruan J, Bond DA, Shah B, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D et al..  2026.  MRD-driven initial therapy of acalabrutinib and lenalidomide plus rituximab or obinutuzumab for mantle cell lymphoma.. Blood Adv. 10(4):1381-1394.

Ruan J, Bond DA, Shah BD, Allan JN, Rutherford SC, Gribbin C, Chen Z, Bhinder B, Tam W, Rossi D et al..  2025.  MRD-driven Initial Therapy of Acalabrutinib and Lenalidomide plus Rituximab (ALR) or Obinutuzumab (ALO) for Mantle Cell Lymphoma.. Blood Adv.

Ruan J, Moskowitz A, Mehta-Shah N, Sokol L, Chen Z, Kotlov N, Nos G, Sorokina M, Maksimov V, Sboner A et al..  2023.  Multicenter phase 2 study of oral azacitidine (CC-486) plus CHOP as initial treatment for PTCL.. Blood. 141(18):2194-2205.

Shah MA, Enzinger P, Ko AH, Ocean AJ, Philip PAgop, Thakkar PV, Cleveland K, Lu Y, Kortmansky J, Christos PJ et al..  2020.  Multicenter Phase II Study of Cabazitaxel in Advanced Gastroesophageal Cancer: Association of HER2 Expression and M2-Like Tumor-Associated Macrophages with Patient Outcome.. Clin Cancer Res. 26(18):4756-4766.

Elemento O.  2026.  Multi-Hospital Electronic Health Record Foundation Models Without Data Sharing: A Comparison of Federated Learning and Inference-Time Ensembling.. medRxiv.

Surapaneni S, Kutler RB, Setzen SA, Kim YEun, Yao P, Siddiqui SH, Pitman MJ, Sulica L, Elemento O, Khosravi P et al..  2026.  A Multimodal Approach for Deep-Learning Classification of Vocal Fold Pathologies in Stroboscopy.. Laryngoscope.

Scarpa JR, Elemento O.  2023.  Multi-omic molecular profiling and network biology for precision anaesthesiology: a narrative review.. Br J Anaesth. 131(1):26-36.

Bojmar L, Zambirinis CP, Hernandez JM, Chakraborty J, Shaashua L, Kim J, Johnson KEnnu, Hanna S, Askan G, Burman J et al..  2024.  Multi-parametric atlas of the pre-metastatic liver for prediction of metastatic outcome in early-stage pancreatic cancer.. Nat Med. 30(8):2170-2180.

Bunting KL, T Soong D, Singh R, Jiang Y, Béguelin W, Poloway DW, Swed BL, Hatzi K, Reisacher W, Teater M et al..  2016.  Multi-tiered Reorganization of the Genome during B Cell Affinity Maturation Anchored by a Germinal Center-Specific Locus Control Region.. Immunity. 45(3):497-512.

Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J et al..  2020.  Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response.. Cancer Cell. 37(5):655-673.e11.

Xiao G, Annor GK, Harmon KW, Chavez V, Levine F, Ahuno S, Atmane MI, St Jean S, Rowdo FPMadorsky, Leybengrub P et al..  2026.  Mutant p53 Directs PARP to Regulate Replication Stress and Drive Breast Cancer Metastasis.. bioRxiv.

Nie K, Redmond D, Eng KW, Zhang T, Cheng S, Mathew S, Elemento O, Tam W.  2021.  Mutation landscape, clonal evolution pattern, and potential pathogenic pathways in B-lymphoblastic transformation of follicular lymphoma.. Leukemia. 35(4):1203-1208.

Mlynarczyk C, Teater M, Pae J, Chin CR, Wang L, Arulraj T, Barisic D, Papin A, Hoehn KB, Kots E et al..  2023.   mutation yields supercompetitive B cells primed for malignant transformation.. Science. 379(6629):eabj7412.

Rajadhyaksha AM, Elemento O, Puffenberger EG, Schierberl KC, Xiang JZ, Putorti ML, Berciano J, Poulin C, Brais B, Michaelides M et al..  2010.  Mutations in FLVCR1 cause posterior column ataxia and retinitis pigmentosa.. Am J Hum Genet. 87(5):643-54.

Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P et al..  2023.  Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.. Nat Commun. 14(1):8435.

Altorki NK, McGraw TE, Borczuk AC, Saxena A, Port JL, Stiles BM, Lee BE, Sanfilippo NJ, Scheff RJ, Pua BB et al..  2021.  Neoadjuvant durvalumab with or without stereotactic body radiotherapy in patients with early-stage non-small-cell lung cancer: a single-centre, randomised phase 2 trial.. Lancet Oncol. 22(6):824-835.

Podaza E, Kuo H-H, Nguyen J, Elemento O, M Martin L.  2022.  Next generation patient derived tumor organoids.. Transl Res. 250:84-97.